… for autologous stem cell transplantation (ASCT). Additional … disease presentation, patients
with acute renal failure due to … Alternatively, patients can undergo stem cell collection after 4 …

… After induction therapy, she had an autologous stem cell … acute kidney injury (AKI) with
methotrexate administration can occur … Etoposide is a topoisomerase II inhibitor that prevents DNA …

… of cyclophosphamide and carmustine prompted consideration of … eligibility for autologous
stem cell transplantation is indicated… consensus criteria) following the described intervention, …

… or autologous hematopoietic stem cell transplantation (HSCT)… day +100 post-HSCT and
survival at day +180 post-HSCT in … , prior solid organ transplant, dialysis dependence at the time …

… , cytarabine, etoposide, melphalan, carmustine, thiotepa, … after pediatric allogeneic
hematopoietic cell transplantation for … of acute kidney injury (AKI) is less frequent in autologous …

… Acute kidney injury is frequently a component and mimics the … glomerular filtration rate or
dialysis; dialysis does not affect … patients after hematopoietic stem cell transplantation. Biol …

… When a patient begins the hematopoietic cell transplantation (HCT… medications on days
of etoposide administration. … 2–3 times daily during and for 24 hours post high-dose thiotepa …

… within 1 year of autologous stem cell transplant (ASCT). … post-ASCT within 12 months relapsed
post-ASCT within 12 … (CRS) comprising grade 4 acute kidney injury on day 6. The grade 4 …

… public attention following the increased incidence of severe … and therapy with fludarabine,
carmustine, melphalan, and ATG … initiated as the patient had acute kidney failure. Therapy with …

… for use of stem cell transplant in autoimmune disease were … autologous HCT is related to
repopulation after transplant … and myeloablative BEAM (carmustine, etoposide, cytarabine, and …